Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. The Company’s research and development focus is on the treatment of patients with hepatitis C virus (HCV). The Company’s HCV discovery program is focused on nucleotide polymerase inhibitors and NS5A inhibitors with its ultimate goal of combining its nucleotide prodrug with its NS5A inhibitor for an internally-developed pan-genotypic regimen. The Company’s lead drug candidate from its NS5A inhibitor program is samatasvir, also known as IDX719, which has demonstrated potent, pan-genotypic activity with once-daily dosing in preclinical and proof-of-concept studies. The Company developed a non-nucleoside reverse transcriptase inhibitor, or NNRTI, drug candidate, IDX899, for the treatment of human immunodeficiency virus type-1 (HIV).